TY - JOUR
T1 - Commissioning and clinical implementation of an Autoencoder based Classification-Regression model for VMAT patient-specific QA in a multi-institution scenario
AU - Yang, Ruijie
AU - Yang, Xueying
AU - Wang, Le
AU - Li, Dingjie
AU - Guo, Yuexin
AU - Li, Ying
AU - Guan, Yumin
AU - Wu, Xiangyang
AU - Xu, Shouping
AU - Zhang, Shuming
AU - Chan, Maria F.
AU - Geng, Lisheng
AU - Sui, Jing
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/8
Y1 - 2021/8
N2 - Background and purpose: To commission and implement an Autoencoder based Classification-Regression (ACLR) model for VMAT patient-specific quality assurance (PSQA) in a multi-institution scenario. Materials and methods: 1835 VMAT plans from seven institutions were collected for the ACLR model commissioning and multi-institutional validation. We established three scenarios to validate the gamma passing rates (GPRs) prediction and classification accuracy with the ACLR model for different delivery equipment, QA devices, and treatment planning systems (TPS). The prediction performance of the ACLR model was evaluated using mean absolute error (MAE) and root mean square error (RMSE). The classification performance was evaluated using sensitivity and specificity. An independent end-to-end test (E2E) and routine QA of the ACLR model were performed to validate the clinical use of the model. Results: For multi-institution validations, the MAEs were 1.30–2.80% and 2.42–4.60% at 3%/3 mm and 3%/2 mm, respectively, and RMSEs were 1.55–2.98% and 2.83–4.95% at 3%/3 mm and 3%/2 mm, respectively, with different delivery equipment, QA devices, and TPS, while the sensitivity was 90% and specificity was 70.1% at 3%/2 mm. For the E2E, the deviations between the predicted and measured results were within 3%, and the model passed the consistency check for clinical implementation. The predicted results of the model were the same in daily QA, while the deviations between the repeated monthly measured GPRs were all within 2%. Conclusions: The performance of the ACLR model in multi-institution scenarios was validated on a large scale. Routine QA of the ACLR model was established and the model could be used for VMAT PSQA clinically.
AB - Background and purpose: To commission and implement an Autoencoder based Classification-Regression (ACLR) model for VMAT patient-specific quality assurance (PSQA) in a multi-institution scenario. Materials and methods: 1835 VMAT plans from seven institutions were collected for the ACLR model commissioning and multi-institutional validation. We established three scenarios to validate the gamma passing rates (GPRs) prediction and classification accuracy with the ACLR model for different delivery equipment, QA devices, and treatment planning systems (TPS). The prediction performance of the ACLR model was evaluated using mean absolute error (MAE) and root mean square error (RMSE). The classification performance was evaluated using sensitivity and specificity. An independent end-to-end test (E2E) and routine QA of the ACLR model were performed to validate the clinical use of the model. Results: For multi-institution validations, the MAEs were 1.30–2.80% and 2.42–4.60% at 3%/3 mm and 3%/2 mm, respectively, and RMSEs were 1.55–2.98% and 2.83–4.95% at 3%/3 mm and 3%/2 mm, respectively, with different delivery equipment, QA devices, and TPS, while the sensitivity was 90% and specificity was 70.1% at 3%/2 mm. For the E2E, the deviations between the predicted and measured results were within 3%, and the model passed the consistency check for clinical implementation. The predicted results of the model were the same in daily QA, while the deviations between the repeated monthly measured GPRs were all within 2%. Conclusions: The performance of the ACLR model in multi-institution scenarios was validated on a large scale. Routine QA of the ACLR model was established and the model could be used for VMAT PSQA clinically.
KW - Clinical implementation
KW - Commissioning
KW - Machine learning
KW - Multi-institution validation
KW - VMAT patient-specific QA
UR - https://www.scopus.com/pages/publications/85109128905
U2 - 10.1016/j.radonc.2021.06.024
DO - 10.1016/j.radonc.2021.06.024
M3 - 文章
C2 - 34166717
AN - SCOPUS:85109128905
SN - 0167-8140
VL - 161
SP - 230
EP - 240
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
ER -